-
Drug, Healthcare and Patient Safety
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
TNF-α inhibitors: are they carcinogenic?
Review
(1541) Views (460) Full article downloads
Authors: αGirindra Raval, Paulette Mehta
Published Date December 2010
Volume 2010:2 Pages 241 - 247
DOI: http://dx.doi.org/10.2147/DHPS.S7829
Girindra Raval1, Paulette Mehta2,31Jefferson Regional Medical Center, Jefferson Hills, PA, USA; 2Department of Internal Medicine (Hematology/Oncology), UAMS, Little Rock, AR, USA; 3Central Arkansas Veterans Healthcare System, Little Rock, AR, USA
Abstract: Biologic therapy has increasingly been used in the treatment of chronic diseases. Tumor necrosis factor (TNF) is a cytokine implicated in the pathogenesis of rheumatoid arthritis and inflammatory bowel disease. Anti-TNF therapy is being used in the treatment of these conditions. Since the introduction of anti-TNF agents, there have been many case reports of development of malignancy after the initiation of anti-TNF therapy. With increasing case reports, there is growing concern that anti-TNF therapy, albeit useful in the treatment of these chronic conditions, might be associated with the development of malignancy in patients. In this review we examine the different anti-TNF agents and different studies to evaluate any possible association between use of any anti-TNF agent and development of malignancy.
Keywords: tumor necrosis factor inhibitor, malignancy, rheumatoid arthritis, inflammatory bowel disease
Readers of this article also read:
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
ABO and rhesus blood group distribution in Kurds
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




